What is the aim of disease-modifying therapies in multiple sclerosis?

The aim of disease-modifying therapies (DMTs) in multiple sclerosis is to reduce the frequency and severity of attacks. DMTs are designed to modify the disease course rather than cure it, which is a crucial distinction. These therapies work by targeting the underlying immune processes that contribute to the demyelination and inflammation characteristic of MS. By doing so, they help to decrease the number of relapses (attacks) experienced by patients, which can significantly improve quality of life and long-term outcomes.

Additionally, while some DMTs may have secondary effects that can contribute to improving overall health and well-being, their primary function remains focused on managing the relapsing nature of MS. This is evident in the way these therapies have been studied and integrated into treatment plans, aiming to stabilize the disease and reduce progression of disability associated with multiple sclerosis.

Other options such as curing the disease, improving muscle strength, and providing immediate pain relief, do not align with the primary goals of DMTs. A cure for MS has not yet been discovered, and while symptom management is an important aspect of the overall treatment strategy, DMTs specifically concentrate on modifying the disease process itself rather than offering immediate relief from symptoms or enhancing muscle strength directly.